Rekha Hemrajani - Net Worth and Insider Trading

Rekha Hemrajani Net Worth

The estimated net worth of Rekha Hemrajani is at least $25,290 dollars as of 2024-06-14. Rekha Hemrajani is the Director of ALX Oncology Holdings Inc and owns about 3,000 shares of ALX Oncology Holdings Inc (ALXO) stock worth over $25,290. Details can be seen in Rekha Hemrajani's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Rekha Hemrajani has not made any transactions after 2020-07-21 and currently still holds the listed stock(s).

Transaction Summary of Rekha Hemrajani

Rekha Hemrajani Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Rekha Hemrajani owns 6 companies in total, including ALX Oncology Holdings Inc (ALXO) , Adverum Biotechnologies Inc (ADVM) , and Aravive Inc (ARAV) among others .

Click here to see the complete history of Rekha Hemrajani’s form 4 insider trades.

Insider Ownership Summary of Rekha Hemrajani

Ticker	Comapny	Transaction Date	Type of Owner
ALXO	ALX Oncology Holdings Inc	2020-07-21	director
ADVM	Adverum Biotechnologies Inc	2019-05-01	director
ARAV	Aravive Inc	2020-01-09	director & President and CEO
		2019-03-25	See Remarks
		2021-07-29	director
		2020-11-18	director & Chief Executive Officer

Rekha Hemrajani Latest Holdings Summary

Rekha Hemrajani currently owns a total of 1 stock. Rekha Hemrajani owns 3,000 shares of ALX Oncology Holdings Inc (ALXO) as of July 21, 2020, with a value of $25,290.

Latest Holdings of Rekha Hemrajani

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
ALXO	ALX Oncology Holdings Inc	2020-07-21	3,000	8.43	25,290

Holding Weightings of Rekha Hemrajani

Rekha Hemrajani Form 4 Trading Tracker

According to the SEC Form 4 filings, Rekha Hemrajani has made a total of 1 transactions in ALX Oncology Holdings Inc (ALXO) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in ALX Oncology Holdings Inc is the acquisition of 3,000 shares on July 21, 2020, which cost Rekha Hemrajani around $57,000.

Insider Trading History of Rekha Hemrajani

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Rekha Hemrajani Trading Performance

GuruFocus tracks the stock performance after each of Rekha Hemrajani's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Rekha Hemrajani is 38.74%. GuruFocus also compares Rekha Hemrajani's trading performance to market benchmark return within the same time period. The performance of stocks bought by Rekha Hemrajani within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Rekha Hemrajani's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Rekha Hemrajani

Average Return

Average return per transaction

Outperforming Transactions

1 out of 1 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	46.47
Relative Return to S&P 500(%)	42.18

Rekha Hemrajani Ownership Network

Ownership Network List of Rekha Hemrajani

No Data

Ownership Network Relation of Rekha Hemrajani

Rekha Hemrajani Owned Company Details

What does ALX Oncology Holdings Inc do?

Who are the key executives at ALX Oncology Holdings Inc?

Rekha Hemrajani is the director of ALX Oncology Holdings Inc. Other key executives at ALX Oncology Holdings Inc include director & President and CEO Jaume Pons , Chief Medical Officer Sophia Randolph , and director & 10 percent owner Jason Lettmann .

ALX Oncology Holdings Inc (ALXO) Insider Trades Summary

Over the past 18 months, Rekha Hemrajani made no insider transaction in ALX Oncology Holdings Inc (ALXO). Other recent insider transactions involving ALX Oncology Holdings Inc (ALXO) include a net sale of 113,208 shares made by Jaume Pons , a net sale of 10,528 shares made by Shelly Pinto , and a net sale of 13,605 shares made by Sophia Randolph .

In summary, during the past 3 months, insiders sold 122,000 shares of ALX Oncology Holdings Inc (ALXO) in total and bought 0 shares, with a net sale of 122,000 shares. During the past 18 months, 138,228 shares of ALX Oncology Holdings Inc (ALXO) were sold and 4,400 shares were bought by its insiders, resulting in a net sale of 133,828 shares.

ALX Oncology Holdings Inc (ALXO)'s detailed insider trading history can be found in Insider Trading Tracker table.

ALX Oncology Holdings Inc Insider Transactions

No Available Data

What does Adverum Biotechnologies Inc do?

Who are the key executives at Adverum Biotechnologies Inc?

Rekha Hemrajani is the director of Adverum Biotechnologies Inc. Other key executives at Adverum Biotechnologies Inc include Chief Development Officer Setareh Seyedkazemi , Chief Financial Officer Linda M Rubinstein , and Chief Scientific Officer Brigit Riley .

Adverum Biotechnologies Inc (ADVM) Insider Trades Summary

Over the past 18 months, Rekha Hemrajani made no insider transaction in Adverum Biotechnologies Inc (ADVM). Other recent insider transactions involving Adverum Biotechnologies Inc (ADVM) include a net purchase of 130,000 shares made by Lupher, Jr. Mark L. , a net purchase of 100,000 shares made by Linda M Rubinstein , and a net purchase of 100,000 shares made by James Paul Scopa .

In summary, during the past 3 months, insiders sold 0 shares of Adverum Biotechnologies Inc (ADVM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 6,810 shares of Adverum Biotechnologies Inc (ADVM) were sold and 33,000 shares were bought by its insiders, resulting in a net purchase of 26,190 shares.

Adverum Biotechnologies Inc (ADVM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Adverum Biotechnologies Inc Insider Transactions

No Available Data

What does Aravive Inc do?

Who are the key executives at Aravive Inc?

Rekha Hemrajani is the director & President and CEO of Aravive Inc. Other key executives at Aravive Inc include Chief Commercial Officer Maria Carolina Petrini , Chief Medical Officer Robert B. Geller , and Chief Financial Officer Rudy Howard .

Aravive Inc (ARAV) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Aravive Inc (ARAV) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aravive Inc (ARAV) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Aravive Inc (ARAV)'s detailed insider trading history can be found in Insider Trading Tracker table.

Aravive Inc Insider Transactions

No Available Data

What does Arcus Biosciences Inc do?

Who are the key executives at Arcus Biosciences Inc?

Rekha Hemrajani is the See Remarks of Arcus Biosciences Inc. Other key executives at Arcus Biosciences Inc include See Remarks Jennifer Jarrett , director & 10 percent owner & President Juan C. Jaen , and 10 percent owner Gilead Sciences Inc .

Arcus Biosciences Inc (RCUS) Insider Trades Summary

Over the past 18 months, Rekha Hemrajani made no insider transaction in Arcus Biosciences Inc (RCUS). Other recent insider transactions involving Arcus Biosciences Inc (RCUS) include a net sale of 223,626 shares made by Jennifer Jarrett , a net sale of 38,443 shares made by Juan C. Jaen , and a net sale of 8,506 shares made by Goeltz Ii Robert C. .

In summary, during the past 3 months, insiders sold 25,000 shares of Arcus Biosciences Inc (RCUS) in total and bought 0 shares, with a net sale of 25,000 shares. During the past 18 months, 286,423 shares of Arcus Biosciences Inc (RCUS) were sold and 16,248,095 shares were bought by its insiders, resulting in a net purchase of 15,961,672 shares.

Arcus Biosciences Inc (RCUS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Arcus Biosciences Inc Insider Transactions

No Available Data

What does MaxCyte Inc do?

Who are the key executives at MaxCyte Inc?

Rekha Hemrajani is the director of MaxCyte Inc. Other key executives at MaxCyte Inc include EVP and General Counsel Maher Masoud , director & President and CEO Douglas Doerfler , and EVP & Global Sales Thomas M. Ross .

MaxCyte Inc (MXCT) Insider Trades Summary

Over the past 18 months, Rekha Hemrajani made no insider transaction in MaxCyte Inc (MXCT). Other recent insider transactions involving MaxCyte Inc (MXCT) include a net sale of 360,000 shares made by Douglas Doerfler , a net sale of 60,000 shares made by John Joseph Johnston , and a net sale of 116,533 shares made by Thomas M. Ross .

In summary, during the past 3 months, insiders sold 5,000 shares of MaxCyte Inc (MXCT) in total and bought 100,000 shares, with a net purchase of 95,000 shares. During the past 18 months, 536,533 shares of MaxCyte Inc (MXCT) were sold and 180,000 shares were bought by its insiders, resulting in a net sale of 356,533 shares.

MaxCyte Inc (MXCT)'s detailed insider trading history can be found in Insider Trading Tracker table.

MaxCyte Inc Insider Transactions

No Available Data

What does Jiya Acquisition Corp do?

Who are the key executives at Jiya Acquisition Corp?

Rekha Hemrajani is the director & Chief Executive Officer of Jiya Acquisition Corp. Other key executives at Jiya Acquisition Corp include 10 percent owner Glazer Capital, Llc , 10 percent owner Paul J Glazer , and director & 10 percent owner Srinivas Akkaraju .

Jiya Acquisition Corp (JYAC) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Jiya Acquisition Corp (JYAC) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Jiya Acquisition Corp (JYAC) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Jiya Acquisition Corp (JYAC)'s detailed insider trading history can be found in Insider Trading Tracker table.

Jiya Acquisition Corp Insider Transactions

No Available Data

Rekha Hemrajani Mailing Address

Above is the net worth, insider trading, and ownership report for Rekha Hemrajani. You might contact Rekha Hemrajani via mailing address: 3928 Point Eden Way, Hayward Ca 94545.

Discussions on Rekha Hemrajani

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.